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ministrative data provides an opportunity to examine
this use in the general population. OBJECTIVES: The
study purpose was to investigate how sedative/hypnotic
drugs are used in an ambulatory population. METH-
ODS: A retrospective analysis of prescription claims from
an integrated database. Persons with at least one pre-
scription for a nonbarbiturate sedative/hypnotic in a 36-
month sampling frame (1/1/95–12/31/97) were included.
Sedative/hypnotic agents included: estazolam, ethchlor-
vynol, flurazepam, glutethimide, quazepam, temazepam,
triazolam, and zolpidem. RESULTS: 55,086 persons had
at least one claim for the drugs of interest. 58% were fe-
male, the average age was 62 years  14.5 years, with a
range of 3–104 years. 58% of those identified were 60
years of age. Women were only slightly older than men
(62.1 years compared to 61.8 years). The most com-
monly used agent during the study timeframe was zolpi-
dem (a short-acting agent) with 58% of identified sub-
jects having at least one claim. This was followed by
temazepam (an intermediate acting agent) used by 36%
of persons identified. 53% of persons using zolpidem and
36% of persons using temazepam were 60 years of age.
27% of persons identified had claims evidence suggestive
of single, one time acquisition of a sedative/hypnotic
agent during a 12-month period of time. CONCLUSION:
The majority of persons in this ambulatory population
used short or intermediate acting sedative/hypnotics, for
extended use. A large number of patients 60 years of
age rely on benzodiazepine-based agents (temazepam)
that can produce daytime sedation which may decrease
daytime functioning.
PMH19
ANTIPSYCHOTIC DRUG USE PATTERNS AND 
THE COST OF TREATING SCHIZOPHRENIA: 
DATA FROM THE MEDICAID PROGRAMS OF 
ALABAMA, GEORGIA, KENTUCKY, 
AND MICHIGAN
Lyu RR1, McCombs JS1, Johnstone BM2, Muse DN3
1Department of Pharmaceutical Economics and Policy, School 
of Pharmacy, University of Southern California, Los Angeles, 
CA, USA; 2Health Outcomes Evaluation Group, Eli Lilly and 
Company, Indianapolis, IN, USA; 3Donald N Muse and 
Associates, Washington, DC, USA
OBJECTIVE: This study documented the relationship be-
tween antipsychotic drug use patterns and direct health
care costs for community-dwelling patients with schizo-
phrenia in four state Medicaid programs. METHODS: A
one-year treatment period was defined for each patient
(N  18,090). Logistic regression models were used to
investigate the predictors of not having used any medica-
tion, delaying therapy, changes in therapy, and complet-
ing one year of continuous therapy. Regression analyses
were used to estimate the impact of these patterns of an-
tipsychotic drug use on direct health care costs. RESULTS:
The average annual total direct cost for community-
dwelling patients with schizophrenia was $13,650 (N 
18,090). Approximately 24% of patients did not use any
antipsychotic drug for at least one year and consumed
significantly fewer services ($3,200). Delaying antipsy-
chotic therapy (18%) was associated with an increase in
total cost of care of $3,936 (P  0.0001). Patients who
switched or augmented their initial therapy (41%) were
also found to experience higher total cost of care
($4,019, P  0.0001). Continuous antipsychotic therapy
(18%) was associated with significant shifts in the type of
care consumed ($1,337 in hospital costs; $652 in nurs-
ing home costs; $1,237 in ambulatory services and $939
in other services), leaving total cost unchanged. CONCLU-
SIONS: A significant proportion of patients with schizo-
phrenia treated with traditional antipsychotic medica-
tions did not display drug utilization patterns consistent
with successful drug therapy. Suboptimal drug use pat-
terns were associated with increased direct healthcare costs.
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OBJECTIVE: This study examined medical resource con-
sumption by patients with chronic and breakthrough
pain (BTP) who were using transdermally-delivered fent-
anyl for the management of chronic pain. Patients were
participants in a broader survey designed to collect clini-
cal and economic information regarding their pain.
METHODS: Surveys were administered to cancer and
non-cancer patients with chronic and BTP to assess med-
ical resources consumed in the past 30 days. Patients
were identified from investigator practices and asked to
participate in an interview. Data were collected for physi-
cian contacts, Emergency Department (ED) visits, hospi-
talizations, prescription use, patient work loss, and care-
giver time and work loss. RESULTS: 102 patients were
enrolled at the time of this analysis; 95 (93%) completed
the survey. Forty (42%) were men and 55 (58%) were
women. 42% reported calling and 44% visited their phy-
sician’s office, averaging 1.05 telephone calls and 0.68
visits specifically because of BTP. Patients averaged 2.55
prescriptions for pain control during the period. Twelve
patients (13%) reported 16 ED visits, and 11 patients
(12%) reported 13 hospitalizations. Only 20 of the 95
patients (21%) were working in a paid job. Of these,
70% (14/20) reported lost work, an average of 36.9
hours during the prior 30 days, due to pain. Nearly 83%
of patients reported having someone help with their per-
sonal and/or medical care. Caregivers spent an average of
77 hours helping patients. Twenty-four patients (25%)
reported an average of 24 hours of caregiver work loss as
a result. CONCLUSIONS: The magnitude of medical re-
source consumption due to pain is notable, and lost work
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time is high. Further research with a control group is
needed to determine costs specifically attributed to BTP.
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As pharmaceutical care progresses, pharmacists must con-
tinue to develop their qualitative and quantitative assess-
ment skills. Quality of life (QoL) assessment represents an
important part of the overall outcome evaluation in the
management of depressed patients. OBJECTIVE: The pur-
pose of this prospective study was to document the QoL
reported to community pharmacists by treated ambulatory
depressed patients. METHODS: Pharmacists collected de-
mographic, antidepressant, and SF-36 questionnaire data,
and verified each patient’s antidepressant treatment for at
least three consecutive months. Most patients received their
antidepressant drug as their only medication. RESULTS:
Fifty-seven patients completed SF-36 questionnaires and de-
mographic data forms under the supervision of their com-
munity pharmacists. Thirty-five patients were treated with
SSRI’s while 22 were treated with Non-SSRI’s. Patients re-
ceiving Non-SSRI’s were eight years older on average than
those receiving SSRI’s (P  0.05). Patients receiving SSRI’s
scored statistically higher on five SF-36 Scale scores, in-
cluding physical functioning, role-physical, general health,
vitality, and mental health. Physical component summary
(PCS) scores were statistically higher for SSRI patients
than Non-SSRI patients, with scores of 49.95 and 39.39,
respectively (P  0.05). Mental component summary
(MCS) scores were similar for SSRI patients and Non-
SSRI patients, with scores of 45.02 and 42.48, respec-
tively. CONCLUSION: Non-SSRI patients demonstrated
a statistically poorer QoL in the PCS and related Scale
scores, a finding which is consistent with their older
mean age. These data support the avoidance of Non-SSRI
therapy in older depressed patients. These data also com-
pare favorably with the findings documented in medical
care settings, demonstrating the utility of the SF-36 by
community pharmacists in their usual practice settings.
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Many health-related quality of life instruments are not
useful in clinical practice because of their length and
scoring algorithms. The brief Quality of Life With Mi-
graine (QOLWM) questionnaire was designed as a
screening tool for general use by migraineurs. OBJEC-
TIVE: To determine sensitivity to discriminate among
levels of headache frequency and severity, and medication
usage. METHODS: The previously validated QOLWM
asks about the frequency and impact of seven problem
areas. Migraineurs participated in a web-based survey of
demographic and headache characteristics, use of pre-
scription and non-prescription headache medications,
and quality of life. ANOVA analyses included 994 re-
spondents who completed all QOLWM items. RESULTS:
Patients experiencing a high frequency of headaches (P 
0.0001) and days with severe headaches (P  0.0003) in
the previous month also had significantly lower quality
of life (higher QOLWM Total Scores) than patients re-
porting less frequent and severe episodes. Compared to
patients without such problems, those reporting nausea
(P  0.016), distress with activity (P  0.0001) or light
(P  0.01) had lower QOLWM scores. Patients taking
prescription medications daily (P  0.0001), or who
took prescription drugs at the beginning or during a
headache (P  0.01) also had lower QOLWM scores
than patients who did not use prescription medications.
Patients who took medications only at the headache on-
set (P  0.0001) had lower QOLWM scores than people
who took medication daily. CONCLUSIONS: These
data suggest that the QOLWM could discriminate among
patients with varying headache severity and medication
usage. The QOLWM could be useful for headache assess-
ment in clinical practice.
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Instrument-based scores are often used as outcome mea-
sures. However, little is known about what changes in
scores mean in terms of a clinical assessment of improve-
ment or deterioration. OBJECTIVE: The purpose of this
study was to determine how much change in standard
symptom and HRQOL instrument scores represents a
clinically detectable improvement or deterioration for
schizophrenia patients. METHODS: The VA Coopera-
tive Study of Clozapine in Refractory Schizophrenia eval-
uated 423 patients with clozapine or haloperidol. Symp-
toms (PANSS) and quality of life (QLS) scales were
competed at baseline, 1.5, 3, 6, and 12 months. Changes
were calculated as percentage improvement and as
changes in a mean 7-point item scale based on clinicians’
ratings of patient status compared to baseline. RE-
SULTS: Based on clinician-assessed improvements from
baseline, PANSS scores improved by 21%; QLS scores by
